All In Biotech

BLA 208751 · Novo

Fiasp Penfill

Insulin Aspart · Subcutaneous, Intravenous, Subcutaneous · Insulin Analog

Last checked: Nov 19, 2026Latest source record: Jun 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Sep 29, 2017

Approved uses

4

Original approval plus efficacy supplements

Registered trials

485

129 Phase 3, 9 recruiting

FAERS reports

12,548

10,461 serious, 1,455 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 21, 2023.

FIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. • FIASP is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus ( 1 ).

Mechanism: The primary activity of FIASP is the regulation of glucose metabolism. Insulins, including insulin aspart, the active ingredient in FIASP, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and by inhibiting the output of glucose from the liver. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • FIASP PENFILL · INSULIN ASPART 300 UNITS/3ML (100 UNITS/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • FIASP · INSULIN ASPART 1000 UNITS/10ML (100 UNITS/ML) · SOLUTION, INTRAVENOUS, SUBCUTANEOUS · Prescription
  • FIASP FLEXTOUCH · INSULIN ASPART 300 UNITS/3ML (100 UNITS/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Aspart" as an intervention, any sponsor and status, largest first.

All 485 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased1,093
  • nausea814
  • dyspnoea754
  • hypoglycaemia743
  • vomiting717
  • off label use711
  • drug ineffective643
  • abdominal pain542
  • diarrhoea525
  • condition aggravated522
  • fatigue516
  • acute kidney injury466

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200435
200530
200635
200765
2008110
2009137
2010111
201197
2012146
2013193
2014238
2015311
2016353
2017384
2018711
2019769
2020893
20211,227
20221,291
20231,222
20241,406
20251,610
20261,174

Recalls

3 FDA enforcement reports for this application.

  • Mar 22, 2021 · Class I · Terminated

    Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

  • Mar 22, 2021 · Class I · Terminated

    Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

  • Mar 22, 2021 · Class I · Terminated

    Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fiasp (Insulin Aspart (Niacinamide))

2024 spending

$64.1M

Beneficiaries

26,825

83,323 claims

Per beneficiary

$2,389

$27.79 per unit

View as table
YearSpending
2020$8,960,478
2021$11,997,955
2022$16,947,897
2023$23,960,286
2024$64,072,644

Part D: Fiasp Flextouch (Insulin Aspart (Niacinamide))

2024 spending

$289M

Beneficiaries

131,189

398,663 claims

Per beneficiary

$2,207

$35.44 per unit

View as table
YearSpending
2020$29,337,196
2021$45,295,952
2022$68,499,735
2023$105,895,817
2024$289,492,211

Part D: Fiasp Penfill (Insulin Aspart (Niacinamide))

2024 spending

$4.9M

Beneficiaries

2,286

5,790 claims

Per beneficiary

$2,156

$33.98 per unit

View as table
YearSpending
2020$345,965
2021$790,134
2022$1,263,555
2023$1,637,027
2024$4,929,500

Part B: Fiasp* (Insulin Aspart (Niacinamide)*) · HCPCS J1811

2024 spending

$1.8M

Beneficiaries

1,562

4,313 claims

Per beneficiary

$1,123

2024 ASP limit $7.33 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$711,365
2024$1,754,312

Part B: Fiasp Penfill* (Insulin Aspart (Niacinamide)*) · HCPCS J1817

2024 spending

$55.5M

Beneficiaries

35,179

145,231 claims

Per beneficiary

$1,577

2024 ASP limit $5.12 per unit

View as table
YearSpending
2020$161,240,121
2021$156,744,156
2022$127,065,578
2023$106,195,555
2024$55,491,178

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 481 on PubMed

Sponsor: Novo · Also marketed as Fiasp, Fiasp Flextouch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.